PARIS/NEW YORK, July 9 (Reuters) - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly
Jonathan Koss : Regeneron Pharmaceuticals , Inc . ( REGN ) is a U.S ..... FDA approved Regeneron 's Eylea , a treatment for ..... following two years, Regeneron 's share price ..... predicted success of Eylea and its high sales
July 1 (Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between...
Agency (EMA) approve Regeneron Pharmaceuticals ' ( REGN ) Eylea ( aflibercept ) injection ..... macular edema (DME). Eylea is currently approved ..... occlusion (CRVO). Regeneron and Bayer Healthcare ..... global development of Eylea . Regeneron has exclusive
June 19 (Reuters) - Regeneron Pharmaceuticals Inc : * U.S. judge denies merus bv's bid to dismiss Regeneron Pharmaceuticals inc 's
interrupts the resultant cytokine-mediated inflammatory signalling. Sarilumab is being co-developed by Regeneron Pharmaceuticals ( REGN -0.2% ) and Sanofi ( SNY ). Post your comment!
Regeneron Pharmaceuticals ( REGN ) reports that collaboration ..... European Union for Eylea (aflibercept) for ..... has also approved Eylea for wet AMD and Macular ..... Diabetic Macular Edema. Regeneron has exclusive rights to Eylea in the U.S. Bayer
several significant drugs in the interim. Blockbuster eye disease drug Lucentis is witnessing intense competition from Regeneron 's Eylea , and while we expect the drug to hold its own, we doubt Lucentis will continue to serve as the growth driver it has been
Regeneron reported first-quarter results that ..... disappointing due to sluggish sales of Eylea in the U.S. However, the company ..... first quarter of 2013. Revenue included Eylea U.S. net product sales of $359 million ..... market share trends. Rest-of-world Eylea sales, as reported by partner Bayer
(Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...